SUPN

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.

Wall Street analysts forecast SUPN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SUPN is 60.50 USD with a low forecast of 50.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Supernus Pharmaceuticals Inc revenue for the last quarter amounts to 192.10M USD, increased 9.34 % YoY.

Supernus Pharmaceuticals Inc. EPS for the last quarter amounts to -0.80 USD, decreased -215.94 % YoY.

Supernus Pharmaceuticals Inc (SUPN) has 674 emplpoyees as of December 15 2025.

Today SUPN has the market capitalization of 2.70B USD.